News >

Genomic Assays Continue to Individualize Treatment for HR+ Breast Cancer

Brandon Scalea
Published: Tuesday, May 07, 2019

Sayeh Lavasani, MD, MS

Sayeh Lavasani, MD, MS

Genomic assays are painting a clearer picture of which patients with hormone receptor (HR)–positive breast cancer can receive endocrine therapy alone or do require the addition of chemotherapy, said Sayeh Lavasani, MD, MS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication